Aijaz Ahmed, Associate Professor of Medicine Medical Director – Liver Transplant Program, Division of Gastroenterology and Hepatology, Stanford University School of Medicine
Robert Wong, Assistant Clinical Professor of Medicine, Director of Research and Education, Division of Gastroenterology and Hepatology, Alameda Health System - Highland Hospital
Sammy Saab, Professor of Medicine and Surgery, Pfleger Liver Institute
As the treatment for hepatitis C virus (HCV) continues to advance at an extremely rapid pace with new developments and a rising number of HCV infections among patients with Substance Use Disorders (SUD) a significant educational need presses for practicing health care professionals who manage the care of these patients. This program will provide, with a detailed understanding, the importance of screening, accurate diagnosis and proper treatment of HCV infection among this epidemically growing SUD population.
Learning Objective 1
• Examine data on the prevalence and transmission of the hepatitis C virus (HCV) in the substance use disorder (SUD) population.
Learning Objective 2
• Describe the damaging effects of chronic HCV, thereby emphasizing the need for screening, diagnosis and treatment.
Learning Objective 3
• Review data on the benefits of treating HCV patients with SUDs, with and without concomitant opioid replacement therapy.